Daily Roundup

GNP.ASX LPE.ASX KCN.ASX EMV.ASX SPL.ASX

GenusPlus Lands $55 Million Rio Tinto Contract

Infrastructure services provider GenusPlus Group Ltd has secured a major contract worth approximately $55 million from Rio Tinto to construct a 220kV Millstream Substation expansion in Western Australia's Pilbara region. Work kicks off immediately, with the project expected to wrap up by mid-2028. The company will deploy around 50 personnel to the site, located roughly 80 kilometres south of Karratha. This win represents a significant boost to GenusPlus' order book and deepens its partnership with the mining giant.

LPE Plots Growth With Three Development Partnerships

Locality Planning Energy Holdings Limited has announced three residential development partnerships that should meaningfully expand its footprint. The deals span social and affordable housing, premium townhouse developments, and over-50s communities, targeting 18 sites with more than 3,000 new homes and 4,700 energy and water service points. LPE will invest approximately $5.8 million in capital to support these ventures, which are expected to generate recurring revenue and diversification benefits as the sites come online. The company had briefly suspended trading to finalize the announcement but shares have now resumed trading.

Kingsgate Making Progress on Chatree Mine Repairs

Kingsgate Consolidated Limited provided an encouraging update on remediation efforts at its Chatree Gold Mine in Thailand. Plant 1 has successfully restarted with a modified circuit configuration after the Ball Mill was isolated and the SAG Mill recommissioned. The adjusted setup is now processing approximately 130 wet tonnes per hour, restoring roughly 50% of the plant's normal capacity. Remediation work on the Ball Mill continues to advance, with key components like bearings already removed and replacement lubrication systems being procured. Mining operations have continued uninterrupted throughout the repair period, with the team maximizing ore grades to offset the temporary processing constraints.

EMVision Advances Clinical Programs With Strong Cash Position

Medical device developer EMVision Medical Devices Ltd reported solid progress across its clinical pipeline and a healthy balance sheet. The company surpassed key enrolment milestones in its Pivotal Validation Trial and is preparing to add an acute ischaemia detection endpoint to strengthen its neurodiagnostic device's clinical credentials. A First Responder feasibility study also wrapped up successfully. On the financial front, EMVision secured $2.0 million in grant funding and maintains $17.1 million in cash reserves, with another $4.6 million available under existing grant programs. This financial cushion positions the company well to advance its innovative technology platform.

Starpharma Pushes Forward With Oncology Pipeline and Capital Raise

Biotech company Starpharma Holdings Ltd has completed the preclinical data package for DEP® HER2-Lu, its proprietary radiopharmaceutical candidate, and commenced GMP dendrimer manufacturing ahead of a planned Phase 1 study in the second half of 2026. The company also filed a new patent application covering its DEP® technology in radioligand therapy. A milestone achieved under the Radiopharm Theranostics collaboration triggered a $0.5 million option fee, with the collaboration now moving into its exclusive license option period. Starpharma generated considerable interest at the BIO International Convention, where it showcased opportunities around its Star Navigator platform and DEP® programs.

To fund continued development, Starpharma announced a fully underwritten entitlement offer to raise approximately $32 million. The company will issue roughly 56 million new shares at $0.57 each—a 25% discount to the last closing price—on a one-for-7.5 pro rata basis. Proceeds will extend the company's cash runway into FY28 and support progression of the DEP® HER2-Lu Phase 1 study alongside development of other dendrimer-based oncology assets. Starpharma ended the quarter with $11.0 million in cash, having seen customer receipts surge 149% compared to the prior year.